SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Illustration of abstract tunnel with haematocytes
Drug development
5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit
In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.
October 21, 2024
 · 
4 min read
 · 
Kate Goodwin
Set of two dart targets with arrow and dart. Vector color illustration.
Cancer
With Myriad Recent Approvals in Cancer, The Era of Bispecifics Is Here
As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say the class could overtake monoclonal antibody Keytruda as the “immunotherapy backbone” of solid tumor treatment.
October 14, 2024
 · 
6 min read
 · 
Kate Goodwin
Man inside a boat made with a dollar
M&A
Concentra Spies New Target After Kezar’s Lupus Trial Hold
After four patient deaths, Kezar’s lupus trial is officially on hold, sparking investor Kevin Tang’s interest for acquisition.
October 9, 2024
 · 
1 min read
 · 
Kate Goodwin
South San Francisco, CA, USA - May 1, 2022: Exterior view of the Merck Researches Laboratories in South San Francisco, California. Merck & Co., Inc. is a global pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme (MSD) outside the United States and Canada.
Drug Development
Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab
On the heels of Keytruda’s success in a Phase III perioperative trial for a disease where it had previously failed to improve event-free survival, Merck touts an I&I deal with UK biotech Mestag.
October 8, 2024
 · 
2 min read
 · 
Kate Goodwin
Psychedelic Brain
Psychedelics
MDMA Drug Developers Reprioritize Following Lykos Rejection in PTSD
After the FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disorder, companies are pivoting away from or delaying similar therapeutics targeting the psychiatric disease.
September 30, 2024
 · 
5 min read
 · 
Kate Goodwin
Pictured: Exterior view of the headquarters of the
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
September 27, 2024
 · 
2 min read
 · 
Kate Goodwin
A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Coronavirus. 3d render
Lung cancer
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell lung cancer, but experts stress the need for diverse and overall survival data.
September 18, 2024
 · 
5 min read
 · 
Kate Goodwin
Entrance of the FTC in Washington, DC
Business
Express Scripts Sues FTC, Demands Withdrawal of ‘False and Misleading’ PBM Report
Pharmacy benefit manager Express Scripts announced Tuesday it has filed a lawsuit in federal court in Missouri against the Federal Trade Commission for its “unfair, biased and erroneous” July report on the industry.
September 17, 2024
 · 
2 min read
 · 
Kate Goodwin
Fashionable halftone collage. Concept of wealth, saving, saving and saving money. Money bag with dollar stacks and stacks of coins. Vector illustration of business and finance for web banner, social media banner, marketing material. Vector illustration
Funding
Terns Announces $125M Raise on Heels of Oral GLP-1 Data Drop
Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big names like Lilly, Pfizer and Roche.
September 10, 2024
 · 
1 min read
 · 
Kate Goodwin
External view of Eli Lilly's world headquarters in Indianapolis
Deals
Lilly, Haya Ink Potential $1B Drug Discovery Deal to Target Obesity and Metabolic Conditions
Under a multi-year agreement announced Wednesday, Eli Lilly will leverage Haya Therapeutics’ proprietary RNA-guided genome platform to identify drug targets to address the chronic conditions.
September 4, 2024
 · 
2 min read
 · 
Kate Goodwin
An eye and DNA
Gene Therapy
Beyond Rare Disease: Wet AMD Gene Therapy Could Reach Millions
With gene therapies by REGENXBIO and AbbVie, Adverum and others in mid- or late-stage trials, this therapeutic class could soon be an option for this common cause of blindness in the elderly.
September 3, 2024
 · 
7 min read
 · 
Kate Goodwin
Deals
Biopharma VC Funding in Q2 Reaches Highest Quarterly Level Since 2022
Venture capital in the sector hit $9.2 billion in the second quarter of 2024, up from $7.4 billion in Q1, while exits fell on a slower M&A cycle and picky IPO market.
August 23, 2024
 · 
3 min read
 · 
Kate Goodwin
Novartis head office building in Dorval, Quebec, Canada
Business
Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis
Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.
August 22, 2024
 · 
2 min read
 · 
Kate Goodwin
Johnson & Johnson's business center in Switzerland
FDA
J&J’s Rybrevant Combo Gets FDA Approval as First Chemo-Free Treatment for NSCLC
Johnson & Johnson announced Tuesday that the FDA has approved Rybrevant with Lazcluze as a first-line chemotherapy-free treatment for patients with EGFR-mutated non-small cell lung cancer.
August 20, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Novavax/Getty Images, STR/NurPhoto
Business
Novavax Misses Q2 Revenue Estimate, Cuts 2024 Forecast on COVID-19 Vaccine Sales
The vaccine maker on Thursday reported $415.5 million in total revenue in the second quarter, lower than the analyst consensus of $458.6 million.
August 8, 2024
 · 
1 min read
 · 
Kate Goodwin
Load More